

Update on Asthma Guidelines

Lauren Benton

Assistant professor

University of Arizona Pediatric Pulmonary

Steele Children's Research Center

Asthma and Airway Disease Research Center

Disclosure

I have nothing to disclose as a conflict of interest for this presentation




Goals

- 1. Review how to diagnose asthma in pediatrics.
- 2. Be familiar with and know the similarities and difference in the step therapies presented in Global Initiative for Asthma 2023 and National heart lung and blood institute 2020 guidelines for each age group.
- Be able to explain what single maintenance and reliever therapy is and when and why to use for patients.
- 4. Learn which controller inhaler that contain inhaled corticosteroids can be used as an as needed medication and when to use these for mild intermittent asthmatics



Defining asthma

- A history of respiratory symptoms that vary over time AND variable expiratory limitations
- Symptoms are triggered by infections, exercise, laughter, allergens, cold air, certain medications, etc
- Chronic airway inflammation




http://www.medifee.com/blog/wp-content/uploads/2015/02/asthma.png



Pulmonary Function Testing

- Obtaining accurate and reliable PFTs is difficult and requires training
- FEV1/FVC <85% of predicted in children
- Significant bronchodilator response: FEV1
 increases from baseline by >12% of the predicted
 after beta agonist (may be absent if in severe
 exacerbation)
- Increase FEV1 by >12% from baseline after 4 wks of ICS
- Average daily diurnal PEF variability is >10%
- Methacholine, exercise, and/or cold air challenge



	Pre	Pred.	%Pred	Post	% Pred	% Change
L	4.30	3.79	113	4.81	127	12
L	2.89	3.26	88	3.99	122	38
%	67.16	86.06	78	82.89	96	23
L	1.98			3.02		52
Lis	1.91	3.57	54	4.18	117	118
	L	L 4.30 L 2.89 % 67.16 L 1.98	L 4.30 3.79 L 2.89 3.26 % 67.16 86.06 L 1.98	L 4.30 3.79 113 L 2.89 3.26 88 % 67.16 86.06 78 L 1.98	L 4.30 3.79 113 4.81 L 2.89 3.26 88 3.99 % 67.16 83.06 78 82.89 L 1.98 3.02	L 4.30 3.79 113 4.81 127 L 2.89 3.26 88 3.99 122 % 67.16 83.06 78 82.89 96 L 1.98 3.02



But is it asthma?

Differential Diagnosis

- Chronic upper airway cough syndrome (postnasal drip)
- Vocal Cord Dysfunction
- Habit Cough
- Gastroesophageal reflux
- Persistent Bacterial Bronchitis
- Primary ciliary dyskinesia
- Interstitial lung disease
- Anatomical abnormalities (vascular compression, subglottic hemangioma, laryngeal web, laryngeal papilloma, etc.)

- Panic attack
- BPD/CLD
- Cystic fibrosis
- Congenital heart disease
- Immunodeficiency
- Connective tissue d/o
- Cystic fibrosis
- Foreign body
- Mediastinal mass
- Recurrent aspiration
- Tracheobronchomalacia
- Congenital heart disease



Modified Asthma Predictive Index (mAPI)

≥4 Wheezing Illnesses and

			* .	
>1	N/I a	In	Crit	Orio
= 1	IVIA	101	CIII	teria

- -Parental asthma
- Atopic dermatitis
 (MD diagnosed)
- -Aeroallergen sensitization

≥2 Minor criteria

- -Food sensitization
- OR -Peripheral blood eosinophils ≥4%
 - -Wheezing apart from colds


Asthma management

Global Strategy for Asthma Management and Prevention (2024 update)

2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.

Guidelines for the Diagnosis and Management of Asthma 2007 (EPR-3)





https://allergyasthmanetwork.or g/wpcontent/uploads/2021/10/Respir atory-Treatments-2024.jpg




Medication Delivery

- Devices for delivery: Nebulizer or MDI (HFA, Breath actuated inhalers, respiClick, respimat, redihalers, dry powder inhalers)
- HFA needs a spacers
 - With mouthpiece or mask
- NO CHILD IS TO YOUNG FOR AN INHALER AND SPACER
- EVERY ASTHMATIC SHOULD HAVE AND ALBUTEROL MDI AND SPACER



Step Therapy


- When changing meds recheck asthma control in 2-3 months
- If well controlled for 3 months step down
- Step up if symptoms are uncontrolled for 2-3 months despite good adherence and technique and lack of modifiable risk factors
- Consider step up for 1-2 week if trigger like allergies or virus is present





Asthma Control

- Rule of 2s
- Asthma control test
- Childhood asthma control test





https://i0.wp.com/post.healthline.com /wp-content/uploads/2023/05/HL-2936112-asthma-control-test-1296-2-2-1296x2060.jpg?w=1155&h=4330



<u>Single Maintenance And Reliever Therapy SMART</u> <u>Anti-Inflammatory Reliever therapy AIR</u>

- AIR: GINA guidelines use AIR for any asthmatic over the age 12
- SMART: ICS-formoterol recommended for children over the age of 5 with moderate asthma
 - NOT SALMETEROL (ADVAIR or Airduo)
 - Max dose < 12 years of age is 8 puffs per day
 - Max dose children 12 or older is 12 puffs per day
- Reduced exacerbations
- Improved asthma control
- Issues
 - Not FDA approved
 - Inhaler supply










Long-acting Muscarinic antagonist

- Patients 12 years and older with uncontrolled persistent asthma, recommends against adding LAMA to ICS compared to adding LABA to ICS.
- Patient over 12 who cannot take a LABA, recommends adding LAMA to ICS controller therapy compared to continuing the same dose of ICS alone
- If a LABA cannot be used adding a LAMA is an acceptable alternative








School age

ICS= inhaled corticosteroid LAMA= long-acting muscarinic antagonist SABA=short acting beta agonist

Consider Biologics



formoterol

Consider


Omalizumab

Pre-school age

VI

A N LAMA= long-acting muscarinic antagonist SABA=short acting beta agonist

ICS= inhaled corticosteroid



ט [Reliever. Pr	NIN SADA				J
NHLBI ≤ 4 years	PRN SABA And can start short course of ICS at start of respiratory tract illness	Daily low- dose ICS and PRN SABA Consider referral to specialist	Daily and PRN low-dose ICS- LABA or daily low-dose ICS + Montelukast or daily medium dose ICS and PRN SBA Refer to specialist	Daily medium-dose ICS-LABA and PRN SABA	Daily high-dose ICS-LABA and PRN SABA	Daily high-dose ICS- LABA + oral systemic corticosteroids and PRN SABA

Fractional Exhaled Nitric Oxide

- Only for children 5 years or older
- May be a useful adjunct to the evaluation when asthma diagnosis is uncertain
- May be used as part of ongoing asthma monitoring and management
- Do NOT use FeNO in isolation for assessing asthma control, predicting future exacerbation and assessing exacerbation severity
- Do NOT us FeNO to predict development of asthma in children 0-4 y/o with recurrent wheezing





Nonpharmacological treatments

- Bottle/sippy cup in bed
- Is asthma an accurate diagnosis
- Are there asthma comorbidities
- Adherence and technique
- Asthma triggers and mitigation techniques
 - Allergy mitigation only a multicomponent is sensitized and symptomatic
 - Integrated pest management symptomatic or sensitized
 - Avoid tobacco exposure and vaping
- Regular activity/exercise
- Pulmonary rehabilitation/Breathing exercises
- Weight reduction
- Avoid environmental pollutants
- Check to see about other medications: Aspirin, NSAID, b-adrenergic blockers or angiotensin converting enzyme inhibitors
- Don't live in a bubble
- Asthma action plans
- Keep vaccinations up to date



Asthma comorbidities

- Anxiety and depression
- GERD
- Obstructive sleep apnea
- Rhinosinusitis
- Vocal cord dysfunction
- Hormonal influence: menses, menopause, thyroid
- Obesity



Thank you Questions?